Theratechnologies completed discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the proposed trial design and protocol for a Phase 3 clinical trial evaluating tesamorelin for the treatment of NASH. The Company is currently evaluating opportunities to most effectively execute this program, including seeking a potential partner for late-stage development.

Further details will be announced as they are finalized.